Consun Pharmaceutical Group (HKSE:01681) Total Liabilities : HK$1,738 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Total Liabilities?

Consun Pharmaceutical Group's Total Liabilities for the quarter that ended in Dec. 2023 was HK$1,738 Mil.

Consun Pharmaceutical Group's quarterly Total Liabilities declined from Dec. 2022 (HK$1,623.01 Mil) to Jun. 2023 (HK$1,576.12 Mil) but then increased from Jun. 2023 (HK$1,576.12 Mil) to Dec. 2023 (HK$1,738.32 Mil).

Consun Pharmaceutical Group's annual Total Liabilities declined from Dec. 2021 (HK$1,777.87 Mil) to Dec. 2022 (HK$1,623.01 Mil) but then increased from Dec. 2022 (HK$1,623.01 Mil) to Dec. 2023 (HK$1,738.32 Mil).

Consun Pharmaceutical Group Total Liabilities Historical Data

The historical data trend for Consun Pharmaceutical Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Total Liabilities Chart

Consun Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,559.33

1,699.62

1,777.87

1,623.01

1,738.32

Consun Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															1,777.87	1,518.33	1,623.01	1,576.12	1,738.32

Consun Pharmaceutical Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Consun Pharmaceutical Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1635.195	+	(4.264	+	98.864
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,738

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	6024.528	-	4286.204
	=	1,738

Consun Pharmaceutical Group's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1635.195	+	(4.264	+	98.864
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,738

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	6024.528	-	4286.204
	=	1,738

Consun Pharmaceutical Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (HKSE:01681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Total Liabilities

Traded in Other Exchanges

C1P:Germany

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Executives

An Yubao	2101 Beneficial owner
Li Qian	2101 Beneficial owner
Central Success Developments Limited	2101 Beneficial owner
Aali Resources Limited	2201 Interest of corporation controlled by you
Bos Trustee Limited	2301 Trustee
Zhang Lihua	2202 Interest of your spouse
An Meng	2101 Beneficial owner
Double Grace International Limited	2101 Beneficial owner
Bos Trustee Limited As Trustee	2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines